NCT06932237Recruiting
Immune-mediated Pathogenic Mechanisms of Neuro-PASC in Veterans
Source: ClinicalTrials.gov · Last updated 31 Mar 2026
Brief summary (registry, in English)
Mental health symptoms, including cognitive impairment ("brain fog"), following COVID-19 are of great concern to Veterans. This research seeks to advance understanding of the long-term effects of COVID-19 on neuropsychiatric and neurological functions, identifying clinically relevant biomarkers and directions for developing and testing therapeutic interventions. To accomplish these objectives the investigators are conducting a longitudinal study at two VA medical centers to: 1) assess and monitor cognitive function and psychiatric symptoms in Veterans post-COVID; 2) evaluate biomarkers of inflammation and signaling pathways associated with viral infection and neuropsychiatric function; and 3) integrate neuropsychiatric and neurological findings with biological data to identify biomarkers and clinical endpoints associated with disease progression or severity, as well as those for promoting brain repair and attenuating those symptoms.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 9 Apr 2025
- Start date
- 20 Feb 2025
- Primary completion date
- 31 Mar 2028
- Lead sponsor
- VA Office of Research and Development
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT06932237
What you commit to
- Study type: Observational
- Planned participants: 200
- From 20 Feb 2025 to the primary completion date, 31 Mar 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- history of fibromyalgia or chronic fatigue syndrome prior to SARS-CoV-2 infection
Other illness
- diagnosed with dementia, traumatic brain injury, a neurological syndrome (e.g. Parkinson disease, Alzheimer disease), or other progressive cognitive disorder before SARS-CoV-2 infection
- diagnosed with a mood or psychotic disorder before SARS-CoV-2 infection
- unstable medical conditions or active uncontrolled autoimmune or inflammatory conditions
Who the study is looking for
- Eligible participants will:
- have a history of SARS-CoV-2 infection 4 weeks prior to enrollment, defined as a positive PCR or home antigen test
- be able to give informed consent as determined by brief cognitive exam and evaluation of understanding of the risks, benefits, and voluntary nature of the study
- Additionally, participants enrolled as part of the neuro-PASC group must also:
- currently experience neuro-PASC symptoms, not present prior to infection, as confirmed by the "Long COVID-19 Symptom Assessment" scale, a self-report measure that consists of 46 common COVID-19 sequela symptoms
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| James H. Quillen VA Medical Center, Mountain Home, TN Coordinator of this site? Confirm its status | Mountain Home | United States | Not yet recruiting |
| VA Portland Health Care System, Portland, OR Coordinator of this site? Confirm its status | Portland | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.